|Title:||Biologics switch in psoriasis||Authors:||CHUHSING KATE HSIAO
|Keywords:||adalimumab; biologic switch; brodalumab; etanercept; guselkumab; infliximab; ixekizumab; psoriasis; secukinumab; ustekinumab||Issue Date:||Mar-2019||Publisher:||FUTURE MEDICINE LTD||Journal Volume:||11||Journal Issue:||6||Start page/Pages:||531||Source:||IMMUNOTHERAPY||Abstract:||
Aim: No guidelines exist for biologic switch in psoriasis after treatment failure. Although, switching between TNF-α antagonists has been reviewed, switching information about newer biologics is limited. Materials & methods: We did a thorough systematic review from 'PubMed' and 'Embase', which includes new biologics such as IL-12/IL-23 antagonists, IL-17A antagonists and IL-23 antagonists. Results & conclusion: New biologics such as IL-17 antagonist or IL-23 antagonist show greater responses in bio-experienced patients and could even be used for patients in whom previous treatments failed.
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.